Dr Garry Willinge is an Advisory Board member at the Australia-China Relations Institute at the University of Technology Sydney (UTS:ACRI) and Managing Director of Cbridge Limited (HK), a management consulting, corporate advisory, capital markets and leadership development firm, with clients and partners across Asia (esp. China, HK & Taiwan), USA, South America, UK & Australia.
He has interests in companies across a number of sectors around the world and facilitated early stage companies’ growth, IPO and exits. He is business partner to a Nobel laureate (Medicine) in the field of gastroenterology, with whom he has incorporated Hong Kong companies and PRC Joint venture companies related to cancer diagnostic product development and treatment solutions. He has been living & working in and out of Hong Kong for 18 years.
Dr Willinge is a Fellow of the Australian Institute of Company Directors (AICD) and a Fellow of the Hong Kong Institute of Directors. He is chairman of AICD Hong Kong Advisory Committee. He graduated with a Bachelor of Science Degree from the University of Melbourne. He gained a Graduate Diploma of Company Directors from the University of New England and was awarded a Graduate Diploma of Applied Finance and Investment from the Securities of Institute of Australia. He also completed the INSEAD Asian International Executive Programme and attended a number of Harvard sponsored IBM management programs over many years.
He is an Adjunct Professor of Business Studies at Curtin University in Australia and previously served a full term of nine years on the Advisory Board of Curtin Business School. In November 2013, he received an honorary degree of Doctor of Technology from Curtin University.
Dr Willinge currently serves on Advisory boards and as a non-executive Director and Chairman on a number of unlisted and listed public and private company boards internationally.